Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2833456 | 0.99 | KIT (0.46) | KITRETKDREGFRERBB2 | |
| SCHEMBL13844442 | 0.95 | KIT (0.43) | KITRETKDREGFRERBB2 | |
| SCHEMBL2833476 | 0.91 | EGFR (0.39) | KITRETKDREGFRERBB2 | |
| SCHEMBL16507592 | 0.90 | EGFR (0.53) | KITEGFRERBB2ACHEBACE1 | |
| SCHEMBL2837582 | 0.89 | EGFR (0.42) | KITRETKDREGFRERBB2 | |
| SCHEMBL13090429 | 0.85 | ERBB2 (0.43) | RETKDREGFRERBB2ACHE | |
| SCHEMBL2834365 | 0.85 | ABCG2 (0.51) | EGFRERBB2ACHEBACE1LMNA | |
| SCHEMBL2834806 | 0.80 | EGFR (0.48) | KITKDREGFRERBB2ACHE | |
| Aniline SCHEMBL27816292 | 0.78 | KIT (0.48) | KITRETKDREGFRACHE | |
| SCHEMBL2836761 | 0.78 | ABCG2 (0.43) | EGFRLMNAHPGDALDH1A1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | claimed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | claimed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | claimed |
| EP-2220054-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | Natco Pharma Limited (IN) | 2010-08-25 | — | — | EP | claimed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | claimed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2012-07-05 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-8080558-B2 | 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent | NATCO PHARMA LIMITED (IN) | 2011-12-20 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | NATCO PHARMA LIMITED (IN) | 2010-10-14 | — | — | US | disclosed |
| EP-2220054-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | Natco Pharma Limited (IN) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009057139-A2 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172380-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | KIT 32/4885RET 1946/4885KDR 1909/4885 |
| US-20100261740-A1 | NOVEL 4-(TETRAZOL-5-YL)-QUINAZOLINE DERIVATIVES AS ANTI CANCER AGENT | MKI67, CDKL5, CCNI | KIT 31/4885RET 2020/4885KDR 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.